Clinical trials: Cognitive Therapy
Hearing Disability, Depression
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
The purpose of this study is to see if a mobile-delivered mental health program called Toivoa-002, which combines digital cognitive behavioral therapy (CBT) with personal coaching, can effectively reduce depression in adults with…
- Conditions
- Hearing Disability, Depression, Mobility Disability
- Trial name
- NCT07195292
- Testing
- Toivoa-002 - A digital Cognitive Behavioral Therapy program combined with NBHWC-certified coaching.
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Toivoa Inc
Ischemic Stroke, Post-stroke Cognitive Impairment
Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.
- Trial name
- NCT03202147
- Testing
- Cromolyn
- Sponsor
- AZTherapies, Inc.
Multiple Sclerosis, Relapsing-Remitting
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
This is a prospective, non-interventional, multicenter study to evaluate quality of life (QoL) and influence of cognitive status on QoL in subjects with relapsing-remitting multiple sclerosis (RRMS) during two years of treatment…
- Trial name
- MusiClock (NCT01110993)
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT03789760
- Testing
- SaiLuoTong capsule
- Where
- 29 sites in China
- Volunteers
- 493 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
Relapsing-Remitting Multiple Sclerosis
GER-009-06-AVX Early Therapy in Multiple Sclerosis
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
- Trial name
- FIT (NCT00492570)
- Volunteers
- 230 people
- Sponsor
- Biogen
Insomnia
Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02)
The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.
- Trial name
- NCT05809544
- Testing
- WELT-IP
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- WELT corp
Mild Cognitive Impairment
A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this…
- Trial name
- NCT01594541
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Pamlab, Inc.
Post-Stroke Cognitive Impairment (PSCI)
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
The aim of this trial is to provide evidence that Actovegin has a symptomatic effect in subjects with post stroke cognitive impairment (PSCI) during a six month treatment period compared to subjects administered placebo.
- Trial name
- ARTEMIDA (NCT01582854)
- Testing
- Actovegin
- Where
- 14 sites in Belarus, Kazakhstan and 1 more
- Volunteers
- 503 people
- Sponsor
- Takeda
Breathing, Mouth
Usability of a Breathing-CBT Platform (CBT = Cognitive Behavioural Therapy)
The study will examine the usability of a breathing platform in the home environment. It will be a randomized, open-label crossover study of 10 participants who will complete the CBT and breathing components in their home, prior…
- Trial name
- NCT04776122
- Testing
- Therapy, No device
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ResMed
Schizophrenia
Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.
- Trial name
- SCORE (NCT00255515)
- Testing
- Quetiapine fumarate, conventional treatment for schizophrenia
- Where
- 15 sites in Sweden
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Alzheimer Disease
A Study of LY3439539 in Participants With Alzheimer's Disease
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.
- Trial name
- NCT07598370
- Testing
- LY3439539
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
Mild Cognitive Impairment, MCI
Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment
Cognitive therapy software for improving cognitive function for patients with mild cognitive impairment
- Trial name
- SB-DEX (NCT06264557)
- Testing
- SB-100, Educational book
- Where
- 12 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Rowan
Schizophrenia, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical…
- Conditions
- Schizophrenia, Central Nervous System Diseases, Cognition
- Trial name
- NCT00968851
- Testing
- EVP-6124
- Where
- 31 sites in United States, Russia and 2 more
- Volunteers
- 317 people
- Sponsor
- FORUM Pharmaceuticals Inc
Chronic Insomnia
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
- Trial name
- DREAM (NCT04325464)
- Testing
- PEAR-003A
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- Pear Therapeutics, Inc.
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Dyslipidemia
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
- Trial name
- EBBINGHAUS (NCT02207634)
- Testing
- Evolocumab, Background Statin Therapy
- Where
- 416 sites in United States, Australia and 28 more
- Volunteers
- 1,974 people
- Sponsor
- Amgen
Mild to Moderate Alzheimer Disease, Cognitive Impairment
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.
- Trial name
- NCT02293915
- Testing
- Sodium oligo-mannurarate 900mg
- Where
- 16 sites in China
- Volunteers
- 818 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Chronic Traumatic Brain Injury, TBI (Traumatic Brain Injury)
Cognitive Network Restoration Therapy for Moderate to Severe Traumatic Brain Injury: A Feasibility Study
The purpose of this feasibility clinical investigation is to evaluate the safety and usability of central thalamic deep brain stimulation (CT-DBS) for use in patients with chronic moderate to severe traumatic brain injury (TBI)…
- Trial name
- NCT07730099
- Testing
- Deep brain stimulation
- Volunteers
- 40 people
- Sponsor
- ReEmerge, Inc.